Vanguard Capital Management LLC Reports New 5.05% Stake in Syndax Pharmaceuticals Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, disclosing a new 5.05% ownership stake in Syndax Pharmaceuticals Inc (SNDX). The filing indicates that as of March 31, 2026, Vanguard beneficially owns 4,457,143 shares of common stock. This position represents a significant increase from a previously reported 0% stake, crossing the 5% regulatory threshold. According to the filing, Vanguard Capital Management LLC holds sole dispositive power over all 4,457,143 shares, while maintaining sole voting power over 634,564 shares. The filing includes holdings from various affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. The securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. No other single person's interest in these securities exceeds 5% of the total shares outstanding.